The Fibrinolytic Response To Stanozolol In Normal Subjects

1981 ◽  
Author(s):  
M Greaves ◽  
F E Preston
Keyword(s):  
Degradation Products ◽  
White Cell Count ◽  
Normal Subjects ◽  
Clot Lysis ◽  
Base Line ◽  
Blood Samples ◽  
Fibrin Degradation Products ◽  
Euglobulin Clot Lysis Time ◽  
Group A ◽  
Group B

It has been recognized for a number of years that fibrinolytic activity in patients with various forms of vascular disease may be enhanced by stanozolol (17-β-hydroxy-17α-methyl adrostano {3.2,- c } pyrazole ). However, little is known of its effect in normal healthy individuals. Also it is not known how quickly the drug exerts its effects. Two groups of eight normal healthy adults were studied. Seven subjects were included in both groups. Group A received stanozolol 5mgs b.d. Group B received 5mgs daily. Before receiving the drug, two base line studies were performed on blood samples from each individual. Thereafter, blood samples were taken at 2,7, 10, 17, 24, 31 and 38 days after commencement of treatment. The following investigations were performed - haemoglobin, white cell count, platelet count, euglobulin clot lysis time (ECLT), fibrinogen (Fg), plasminogen (Pg), α2 macroglobulin (α2M), fibrin degradation products, serum albumin, liver enzymes. In Group A statistically significant increases in plasminogen activator activity, measured by the ECLT, and Pg were observed 2 days (P<0.05) and 10 days (P<0.05) respectively after administration of stanozolol; these remained elevated throughout the study. Also, significant reductions of plasma Fg (P<0.01) and α2M (P<0.05) occurred within 7 days of commencement of the drug and these also persisted throughout the six week period of the trial. Similar statistically-significant changes were also observed in Group B subjects in ECLT, Pg, α2M, although the induced changes were less predictable than those observed in Group A. These results indicate that stanozolol exerts significant and persistent enhancement of fibrinolysis in normal individuals.

A Plasma Clot Lysis Assay Based on the Release of Fibrin Degradation Products: Application to the Diagnosis of Hypofibrinolytic States

1990 ◽  
Vol 63 (01) ◽  
pp. 076-081 ◽  
Author(s):  
Pascale Gaussem ◽  
Sophie Gandrille ◽  
Pascale Molho-Sabatier ◽  
Loïc Capron ◽  
Jean-Noël Fiessinger ◽  
...  
Keyword(s):  
Degradation Products ◽  
Venous Occlusion ◽  
Lower Limbs ◽  
Clot Lysis ◽  
Plasma Clot ◽  
Vein Thrombosis ◽  
Fibrin Degradation Products ◽  
Before And After ◽  
Euglobulin Clot Lysis Time ◽  
Pai 1

SummaryUsing a monoclonal antibody-based assay, we measured the fibrin degradation product release in the supernatant of plasma clots obtained before and after venous occlusion (VO) in 30 patients with definite or suspected vascular thrombosis (19 definite and 2 suspected deep vein thrombosis, 6 recurrent superficial thrombophlebitis, 3 arterial occlusions of lower limbs). tPA and PAI-1 concentrations were determined using ELISA assays; the post-occlusion values were corrected for haemoconcentration. The increase in tPA during VO was correlated with haemoconcentration (r = 0.74), but 3 patients had ineffective VO (<2% increase in proteins). The fibrinolytic response to VO was evaluated using the shortening of the time necessary for the release of 200 μg of fibrin degradation products per mg of fibrinogen (Δ T 200). Two among the 27 patients with effective VO were bad responders with a Δ T 200 <3 h (whereas all the others had Δ T 200 >10 h). These patients had respectively a deficient tPA release (Δ tPA = 1 ng/ml) and an elevated PAI-1 level at rest (33 ng/ml). Several other patients were bad responders in terms of tPA release or of shortening of the euglobulin clot lysis time but they had a normal Δ T 200. This plasma clot test reflects the ability of free tPA to bind to fibrin (the amount of which depends on the level of tPA and PAI-1), and may be useful in the diagnosis of a hypofibrinolytic state.

scholarly journals HYPERCHOLESTEROLEMIA;

2014 ◽  
Vol 21 (01) ◽  
pp. 111-115
Author(s):  
Zahidullah Khan ◽  
Inamullah Khan ◽  
Fazle Subhan
Keyword(s):  
Density Lipoprotein ◽  
Base Line ◽  
Inclusion Criteria ◽  
Blood Samples ◽  
Hospital Design ◽  
Single Center Study ◽  
Group A ◽  
The Mean ◽  
Group B ◽  
Study Setting

Objective: To compare the efficacy of Simvastatin with Atorvastatin in loweringLow Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolemia in a tertiarycare hospital. Design: Prospective, observational, single center study. Setting: Department ofMedicine, Khyber Teaching Hospital, Peshawar. Period: December 2011 to December 2012.Subjects and Methods: A total of 200 cases having base line fasting LDL-C level of ≥ 130 mg/dland meeting the inclusion criteria were included in the study through both outpatient department(OPD) and admitted patient. After detailed history and clinical examination, all patients weredivided randomly into two groups, A and B. Patients in Group A were given Simvastatin20mg/day and Group B received Atorvastatin 20mg/day. Fasting blood samples were taken fromthe selected patients in the start of study and after 12 weeks. Results: A total of 200 subjects witha serum LDL-C level ≥ 130 mg/dL were included in the study. They were divided into 2 groupsrandomly, 100 in each group. Each group comprised of 75 male and 25 female. The mean age ingroup A was 52 years and in group B it was 54 years. The age ranges between 40 years and 73years. Mean base LDL-C level was 165 mg/dl in group A and 170mg/dl in group B. Simvastatin 20mg/dl reduced LDL-C level by 26% and Atorvastatin 20mg/dl reduced LDL-C level by 33% after 12weeks of treatment. Conclusions: Atorvastatin is a more effective drug to reduce serum LDLcholesterolthan Simvastatin in the same doses.

Correlation Of Haematological Parameters In Deep Vein Thrombosis

1981 ◽  
Author(s):  
D R Donaldson ◽  
M J Crow ◽  
G A Davies ◽  
S M Rajah ◽  
D A Watson
Keyword(s):  
Clot Lysis ◽  
Platelet Factor ◽  
Treatment Groups ◽  
Vein Thrombosis ◽  
Significant Difference ◽  
At Iii ◽  
Euglobulin Clot Lysis Time ◽  
Group A ◽  
Uptake Test ◽  
Group B

We have evaluated the response of certain haema to logical parameters in patients undergoing elective thoracotomy for pulmonary and oesophageal disease. These patients are part of a continuing DVT study in which prophylaxis is randomised to either i) Heparin 5000 iu 8 hourly s.c. (Group A) or ii) Heparin 2500 iu + Dihydroergotamine (DHE) 0.5 mg 8 hourly s.c. (Group B). Prophylaxis was commenced at the time of premedication and continued for 10 days. DVT was diagnosed by I125 Fibrinogen uptake test, with confirmatory venography if positive. The haema to logical parameters investigated were Antithrombin III (AT III), Euglobulin Clot Lysis Time (ECLT), plasma $-Thromboglobulin (β-Tg), platelet Factor 4 (PF4) and Heparin level. All investigations were performed pre-op. and day 6 post-op. (AT III and ECLT were also measured on day 3).A total of 50 patients have completed the study to date with 25 patients in each treatment group. Eleven patients have developed DVT - 5 in Group A and 6 in Group B. There was no significant difference between the pre-op. values in either group. The post-op. AT III values of patients developing DVT were lower than the two treatment groups. ECLT was significantly prolonged in the two treatment groups post-op. compared to the pre-op. values (p < 0.05 (A) and p < 0.01 (B)), but was not prolonged post-op. in the patients who developed DVT. Plasma β-Tg and PF4 were raised pre-op. with further increases post-op. in all groups. Plasma Heparin concentrations in Group B (0.122 iu/ml) were lower than for Group A (0.182 iu/ml) and the DVT group (0.176 iu/ml).These findings indicate that none of the haematological investigations were able to delineate ‘at risk’ patients. However the development of DVT was significantly correlated (p < 0.05) with the post-op. AT III and ECLT. The use of DHE in the dose cited above did not apparently inhibit the platelet release reaction

scholarly journals AB0393 EFFICACY OF HYDROXYCHLOROQUINE FOR LUPUS NEPHRITIS IN MAINTENANCE PHASE

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1496.2-1496
Author(s):  
M. Watanabe ◽  
Y. Haji ◽  
M. Kato ◽  
T. Ito ◽  
Y. Banno ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Therapeutic Option ◽  
Maintenance Phase ◽  
Base Line ◽  
Prednisolone Dose ◽  
Daily Urine ◽  
Group A ◽  
The Mean ◽  
Group B

Background:Hydroxychloroquine (HCQ) is an essential drug for systemic lupus erythematosus. But in Japan, chloroquine and HCQ remain unavailable until mid 2015 because of a series of lawsuits about its retinal toxicity in the 1970s. There is insufficient knowledge regarding renal protective effect of HCQ.Objectives:We aimed to investigate its efficacy of adding HCQ for Lupus nephritis (LN) as a maintenance-phase therapy.Methods:We conducted an observational retrospective cohort study included patients with LN (n=42) in maintenance-phase in Japan. We reviewed medical records of LN patients aged > 18 years who were initiated HCQ from May 2015 to May 2018. Maintenance phase was defined as stabilization in serum creatinine and urinary segment after induction therapy and who achieved complete or partial remission. The annual change of proteinuria was compared between patients on HCQ who have proteinuria (>0.5g/gCr) or not. Other outcome measures were disease flare, dose of steroids, renal and immunologic features.Results:A total of 42 patients were analyzed and allocated to two groups based on their amount of daily urine protein level: HCQ with proteinuria as group A (>0.5g/gCr, n=14) and HCQ without proteinuria as group B(≦0.5g/gCr, n=28). Both groups were comparable, with mean (SD) age of 36.1 (12.9) years and 37.5 (13.8), female 78.6% and 92.9% in each group, mean (SD) disease duration until HCQ of 3.5 (3.25) and 3.3 (2.9) years in group A and group B, with prednisolone dose at base line of 10.3 (7.1) mg and 7.9 (4.4) mg, respectively. The mean (SD) proteinuria at base line was 1.38 (1.11) g/gCr in group A and 0.20 (0.09) g/gCr in group B and after 12 months, proteinuria decreased in group A (-1.34 g/gCr in group A vs +0.03 g/gCr in group B; p<.001;95% CI,0.305-0.736). No relapse was experienced in group A during the study period.Conclusion:In patients with clinically stable LN but with proteinuria, hydroxychloroquine is a good therapeutic option for achievement of complete remission.Disclosure of Interests:None declared

scholarly journals Effects of Dexmedetomidine on Intraoperative Hemodynamic Responses in Patients Undergoing Laparoscopic Cholecystectomy: A Randomised Double Blind Trial

2021 ◽  
Author(s):  
Dhanashree Dongare ◽  
Smita Gharde
Keyword(s):  
Laparoscopic Cholecystectomy ◽  
Base Line ◽  
Loading Dose ◽  
Double Blind Trial ◽  
Hemodynamic Responses ◽  
Double Blind ◽  
Significant Difference ◽  
Group A ◽  
American Society ◽  
Group B

Background: Dexmedetomidine is selective alpha 2 agonist with sedative sympatholytic, analgesic properties and is used as an anaesthetic adjuvant. We have evaluated the effect of dexmedetomidine on various hemodynamic responses to incidences such as laryngoscopy, endotracheal intubation, exubation and pneumoperitoneum in patients who were undergoing surgeries like laparoscopic cholecystectomy. We have used loading dose of 0.5mcg/kg of inj. Dexmedetomidine given over 10 minutes followed by infusion of a dose of 0.3mcg/kg/hour for the control of hemodynamic response to laparoscopy. Methods: Patient of either sex aged between 18-50 yrs, belongs to ASA I and II (AMERICAN SOCIETY OF ANAESTHESIOLOGY) posted for laparoscopic cholecystectomy were included. Institutional ethical committee clearance was obtained prior to study. After enrolment and valid written consent was taken. 60 patients were enrolled written valid informed consent was taken. Patients were divided into two groups 30 each with computerized randomization. Base line parameters were noted. Observer and patient was blinded for the content of syringe. Group A received injection dexmedetomidine and group B received bolus and infusion of normal saline at same rate. Routine general anaesthesia was instituted. Parameters were noted after induction, after intubation, after co2 insufflation, after 20 min, after 40 min, after co2 deflation, after extubation, after 1 and 2 hrs post-extubation. Results: Group A showed significantly less rise in HR and MAP than Group B. Requirement of intraoperative propofol was more in Group B. There was no significant difference for time taken to awakening in both groups. Conclusion: We found Injection Dexmedetomidine in given doses gave good hemodynamic control with minimal undesired effects during laparoscopy.

Serological survey of the Berlin population

1934 ◽  
Vol 30 (11-12) ◽  
pp. 1206-1206
Author(s):  
Т. Charbet
Keyword(s):  
Serological Survey ◽  
Blood Samples ◽  
Group A ◽  
Group B

Over the course of 11 years, 30,000 blood samples from inpatients were examined. The distribution by group gives the following result: Group 0-31.6%, Group A-42.2%, Group B- 14.7%, and Group AB-6.5%. There was no difference in the groups with regard to gender. For the indicated period of time the percentage, the ratio of groups did not change significantly.

HAEMOSTATIC PARAMETERS, ENDONEURIAL OXYGEN TENSION AND SURAL NERVE HISTOLOGY IN DIABETES MELLITUS

1987 ◽  
Author(s):  
I Ford ◽  
P G Newrick ◽  
R Malik ◽  
F E Preston ◽  
J D Ward ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Oxygen Tension ◽  
Sural Nerve ◽  
Clot Lysis ◽  
Diabetic Patients ◽  
Membrane Thickness ◽  
Basement Membrane Thickness ◽  
Significant Difference ◽  
Group A ◽  
Group B

We have examined coagulation parameters in 15 neuropathic (Group A) and 10 complication-free diabetic patients (Group B). Venesection and sample testing were performed under standard conditions. Group A underwent sural nerve biopsy and 14 also had measurements of endoneurial oxygen tension. Factor VIII related antigen was higher in Group A (l-617u/ml ± 0.67) compared to Group B (0.944u/ml ± 0.26); (mean ± SD; p<.0.05) perhaps suggesting endothelial cell damage, although this did not correlate with capillary basement membrane thickness or endothelial cell number nor with endoneurial oxygen levels. Platelets from Group A were more sensitive to arachidonate than those of Group B, showing aggregation thresholds in platelet rich plasma of 0.36 ± 0.17mM and 0.57 ± 0.9mM respectively compared with 0.65 ± 0.37mM in non-diabetic controls.Platelets from Group A subjects also produced more thromboxane B2 in response to arachidonate than Group B or normal controls (37.95 ± 27.5; 25.5 ± 13.0; 16.55 ± 15-5pmol/107 platelets). Blood fibrinolytic capacity measured by euglobulin clot lysis time, was diminished in NIDDs (post-occlusion ECLT 165.7 mins ± 116.0), compared to IDDs (55.5 ± 34.5) (p<0.05) due at least in part to excess of tissue plasminogen-activator inhibitor, although we found no significant difference in ECLT between Group A and Group B. Interaction between haemostatic and microvascular abnormalities in diabetes may contribute to the pathogenesis of diabetic neuropathy.

Effects of exercise and conditioning on clotting and fibrinolytic activity in men

1987 ◽  
Vol 62 (4) ◽  
pp. 1416-1421 ◽  
Author(s):  
E. W. Ferguson ◽  
L. L. Bernier ◽  
G. R. Banta ◽  
J. Yu-Yahiro ◽  
E. B. Schoomaker
Keyword(s):  
Fibrinolytic Activity ◽  
Blood Clotting ◽  
Degradation Products ◽  
Clot Lysis ◽  
Plasma Clot ◽  
Fitness Program ◽  
Fibrin Degradation Products ◽  
Before And After ◽  
Plasmin Inhibitor ◽  
Sedentary Subjects

Sixty healthy men in three physical fitness categories (sedentary, on no organized fitness program; joggers, running 5–15 miles/wk; and marathoners, running greater than 50 miles/wk) were evaluated for changes in blood clotting and fibrinolytic activity before and after maximum exercise on a treadmill according to the Bruce protocol. The rate of blood clotting, as measured by prothrombin times, partial thromboplastin times and thrombin times, was accelerated by exercise (all P less than 0.005). The ability of euglobulin clots and plasma clots to lyse incorporated 125I-fibrin, termed 125I-euglobulin clot lysis (IEL) and 125I-plasma clot lysis (IPCL), were used as indexes of fibrinolytic activity. Marathoners had greater increases in fibrinolytic activity with exercise (76% compared with 63% for joggers and 55% for sedentary subjects by IEL; 427% compared with 418% for joggers and 309% for sedentary subjects by IPCL; all P less than 0.05). Fibrin degradation products increased with exercise (P less than 0.005 for the total group of 60 subjects). The absolute concentrations of alpha 2-plasmin inhibitor, alpha 2-macroglobulin, and antithrombin III increased with exercise (all P less than 0.005), but when concentrations were corrected for acute shifts of plasma water during exercise, the quantity of these inhibitors actually decreased (all P less than 0.005). The changes in clotting assays with exercise were not significantly correlated with changes in whole blood lactate, blood pyruvate, or rectal temperatures. Fibrinolytic assays before and after exercise correlated poorly to moderately with blood lactates (IEL: r = 0.441 and r = 0.425, respectively; IPCL: r = 0.294 and r = 0.544, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Urinary excretion of glycated protein determined with a specific radioimmunoassay

1991 ◽  
Vol 37 (4) ◽  
pp. 504-507 ◽  
Author(s):  
Chizuko Ukita ◽  
Mitsushige Nishikawa ◽  
Akira Shouzu ◽  
Mitsuo Inada
Keyword(s):  
Urinary Excretion ◽  
Normal Subjects ◽  
Mean Values ◽  
Specific Radioimmunoassay ◽  
Glycated Protein ◽  
Highly Sensitive ◽  
Significant Difference ◽  
Group A ◽  
The Mean ◽  
Group B

Abstract We developed a simple and highly sensitive RIA for glycated protein (GP), and used it to measure GP in serum and urine from 15 normal controls and 30 diabetics (14 with urinary excretion rate of albumin, Ualb less than 15 micrograms/min, group A; nine with 15 less than or equal to Ualb less than or equal to 150 micrograms/min, group B; and seven with Ualb greater than 150 micrograms/min, group C). The mean serum concentration of GP was above normal in all groups of diabetics, and the mean glycation ratios of serum protein (SGP) were higher in groups B and C than in normal subjects. Urinary concentrations of GP also were increased in groups B and C, although the glycation ratio of urinary protein (UGP) was decreased in group C. Consequently, the selectivity of urinary excretion of GP (UGP/SGP) was significantly decreased in group C. Moreover, there was a significant difference in the mean values of selectivity between groups of patients with various degrees of retinopathy. We suggest that measurements of serum and urinary GP are useful to evaluate the progression of diabetic complications.

Toxicity in Uremia 1. Correlation between PTH Levels and Depressed Cell Proliferation

1988 ◽  
Vol 11 (3) ◽  
pp. 155-158 ◽  
Author(s):  
R. Esposito ◽  
M. Manzo ◽  
M. Hohenegger ◽  
M. Pluvio ◽  
N. Lanzetti ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Normal Subjects ◽  
High Plasma ◽  
Depressing Effect ◽  
Group A ◽  
Uremic Patients ◽  
Group B

Cell proliferation is significantly depressed in uremia; to assess the influence of PTH on it, normal lymphocytes were cultured in presence of uremic patients’ serum with low or high plasma PTH levels (Group A; PTH < 2.5 ng/ml; Group B: PTH > 12 ng/ml), and serum of normal subjects (Group C). Cell proliferation was lowered by serum from both groups (p A vs C < 0.004; p B vs C < 0.001). However, the depressing effect was more evident when group B serum was employed (p A vs B< 0.002).

Sign in / Sign up

Export Citation Format

Share Document